NextCure, Inc. (NASDAQ:NXTC) Receives Average Recommendation of “Hold” from Brokerages

Shares of NextCure, Inc. (NASDAQ:NXTC) have received an average rating of “Hold” from the five brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $23.00.

NXTC has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a research report on Monday, April 27th. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th.

Hedge Funds Weigh In On NextCure

Several large investors have recently added to or reduced their stakes in NXTC. Cable Car Capital LP lifted its position in NextCure by 13.1% during the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after buying an additional 88,040 shares during the period. Geode Capital Management LLC lifted its position in NextCure by 18.6% during the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after buying an additional 3,636 shares during the period. Renaissance Technologies LLC lifted its position in NextCure by 18.7% during the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after buying an additional 5,300 shares during the period. Exome Asset Management LLC purchased a new position in NextCure during the fourth quarter worth about $2,341,000. Finally, AWM Investment Company Inc. purchased a new position in NextCure during the fourth quarter worth about $1,665,000. 42.65% of the stock is currently owned by hedge funds and other institutional investors.

NextCure Trading Down 0.3%

NextCure stock opened at $1.65 on Friday. The stock has a market cap of $5.94 million, a PE ratio of -0.10 and a beta of 1.30. The stock has a 50-day moving average price of $6.63 and a 200 day moving average price of $10.20. NextCure has a 52 week low of $1.55 and a 52 week high of $15.74.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, topping analysts’ consensus estimates of ($2.10) by $0.23. On average, equities analysts predict that NextCure will post -7.9 EPS for the current year.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.